KRAS and acute myeloid leukemia: This adverse risk is compounded by co-mutation of RAS pathway genes (NRAS, KRAS, BRAF, NF1, PTPN11, and/or CBL), leading to a dismal overall AML survival of less than 5 months (9, 14–16).